Polymorphism of Interleukin 1 be Polymorphism of Interleukin 1 beta C31T in blood and tissue patients with breast tumors
Polymorphism of Interleukin 1 beta C31T in blood and tissue patients with breast tumors
DOI:
https://doi.org/10.36320/ajb/v16.i2.15057Keywords:
Key words :- breast tumor , genetic suitability, IL1 beta C31TAbstract
A mass of aberrant tissue is called a tumor. Breast tumors can be classified as either "malignant" or "benign," depending on whether they are malignant or non-cancerous. For the purpose of local immunity research and genetic polymorphism analysis of TLR2, seventy (70) breast tumor biopsy patients who were not receiving chemotherapy were included in the study. As a reference group, fifty (50) blood samples were taken from healthy women. A total of one hundred (100) blood samples from breast tumor patients and thirty samples following treatment were tested for the polymorphism of Interleukin 1 beta C31T, The RFLP-PCR results for the IL-1 beta C31 T gene demonstrated a substantial difference between blood benign and malignant cells, with allele C being a dangerous allele in benign cells at (p – 0.07*). Additionally, the genetic influence of TT was shown to be significantly different in malignant versus benign tissue, with a P value of 0.02*.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global Cancer Statistics 2020. Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.(2021). CA Cancer J. Clin. 71, 209–249.
Hatim KS, Laxmikant NS and Mulla T. Patterns and prevalence of benign breast disease in Western India.(2017). IJ of R in M S, 5, 684-688
Schroder K and Tschopp J. The Inflammasomes.(2010). Cell. 140:821–832.
Martínez-Reza I, Díaz L, Barrera D, Segovia-Mendoza M, Pedraza-Sánchez S, Soca-Chafre G, Larrea F and García-Becerra R. Calcitriol Inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1β and TNF-α .(2019).J. Immunol. Res.1–11.
Akisik E and Dalay N. Functional polymorphism of thymidylate synthase, but not of the COMT and IL-18 genes, is associated with breast cancer.( 2007). J Clin Lab Anal;21:97-402.
Eras N, Daloglu FT, Colak T, Guler M and Akbas E.The correlation between IL1β-C31T gene polymorphism and susceptibility to breast cancer . (2019).J Breast Cancer ; 22(2):210-218.
Lee KM, Park SK, Hamajima N, Tajima K., Choi JY, Noh DY, Ahn SH, Yoo KY, Hirvonen A and Kang D. Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.(2006) Breast Cancer Res Treat. 96(2):197-202.
Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, Qin J, Gao J, Ma H, Wang X, Wei Q and Shen H..Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. (2006). Int J Cancer. 15;118(10):2554-8.
Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Inoue M, Hirose K and Tajima K. Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 CT/TT relative to CC genotype. (2002).Jpn J Clin Oncol, 32(10):398-402.
Bangshun He, ZhangY, PanY, Yeqiong Xu, Ling Gu, ChenL and Wang S. Interleukin 1 beta (IL1B) promoter polymorphism and cancer risk: evidence from 47 published studies. .(2011). Mutagenesis, 26, 5, 637–642.
hathal WA, Abd FG. Estimation of Interleukin1 Alpha and beta in serum and tissue with breast tumors patients.(2023). Journal of Survey in Fisheries Sciences .10(3S) 809-814
Shather T S, & Abd F G. Survey the bacterial types in breast tissue and CA13-5 for women with breast disease in Babylon province. (2022). International Journal of Health Sciences, 6(S4), 6198–6208.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Wurood ali, frial Gemeel Abd, Wala Noori Majeed Barem
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
